ENTITY
Giant Biogene

Giant Biogene (2367 HK)

80
Analysis
Consumer StaplesChina
Giant Biogene Holding Co., Ltd researches, develops, manufactures, and distributes, and markets skin treatment products. The Company produces recombinant collagen and rare ginsenosides skin treatment products, functional foods, and other products. Giant Biogene Holding conducts businesses in China.
more
Refresh
bullishGiant Biogene
16 May 2024 18:55

Giant Biogene Placement - Has Been Doing Well but Doesn’t Need the Cash

Giant Biogene (2367 HK) aims to raise up to US$205m via a top-up placement. In this note, we talk about the deal dynamics and run the deal through...

Logo
246 Views
Share
bullishGiant Biogene
20 May 2024 08:55

Giant Biogene (2367.HK) Placement - A Turning Point in Performance Growth Has Emerged

​Giant Biogene's growth is slowing down with uncertain long-term outlook.Selling Class III medical devices faces challenge in marketing.Reasonable...

Logo
278 Views
Share
bullishGiant Biogene
23 Nov 2023 16:22

2024 High Conviction - Giant Biogene - Growth Rate Keeps Moving Higher

Giant Biogene was listed in Hong Kong IPO in 2022. It has done well since and is now trading 45% above its IPO price, but its still cheap.

Logo
436 Views
Share
bearishGiant Biogene
02 May 2023 09:57

Giant Biogene IPO Lock-Up - US$1.7bn Lockup Release Will Increase Free Float by 14x

Giant Biogene raised around US$70m in its Hong Kong IPO, after having downsized the deal and priced it at the low-end. Its six-month lockup will...

Logo
352 Views
Share
bullishL'Occitane
17 Jun 2024 16:04

L’Occitane (973 HK): Share Alternative a Crucial Step Towards the Offer Being Declared Unconditional

An attractive offer and the share alternative facilitate meeting the 90% minimum acceptance condition. This looks like a done deal. At the current...

Logo
171 Views
Share
x